Oxford Asset Management LLP Acquires Shares of 55,526 Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Oxford Asset Management LLP purchased a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 55,526 shares of the company's stock, valued at approximately $440,000.

Other hedge funds have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Amneal Pharmaceuticals in the fourth quarter worth approximately $81,000. Straightline Group LLC acquired a new position in shares of Amneal Pharmaceuticals in the fourth quarter worth approximately $92,000. Cibc World Markets Corp acquired a new position in shares of Amneal Pharmaceuticals in the fourth quarter worth approximately $118,000. Janney Montgomery Scott LLC acquired a new position in shares of Amneal Pharmaceuticals in the fourth quarter worth approximately $121,000. Finally, Fox Run Management L.L.C. increased its holdings in Amneal Pharmaceuticals by 69.0% in the fourth quarter. Fox Run Management L.L.C. now owns 20,435 shares of the company's stock worth $162,000 after purchasing an additional 8,342 shares in the last quarter. 31.82% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have weighed in on AMRX. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $9.00 to $12.00 in a report on Monday, February 24th. Barclays lifted their target price on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an "overweight" rating in a report on Monday, March 3rd. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, Amneal Pharmaceuticals currently has a consensus rating of "Buy" and a consensus price target of $10.80.

Insider Transactions at Amneal Pharmaceuticals

In related news, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the stock in a transaction on Friday, March 14th. The stock was sold at an average price of $8.35, for a total value of $41,750,000.00. Following the completion of the sale, the insider now directly owns 48,578,209 shares of the company's stock, valued at approximately $405,628,045.15. This represents a 9.33 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Gautam Patel sold 80,000 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $8.14, for a total value of $651,200.00. Following the completion of the sale, the director now directly owns 1,888,886 shares of the company's stock, valued at $15,375,532.04. The trade was a 4.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 5,160,000 shares of company stock valued at $43,113,200 over the last ninety days. 26.56% of the stock is owned by company insiders.

Amneal Pharmaceuticals Price Performance

Shares of NASDAQ:AMRX traded down $0.09 during trading on Wednesday, reaching $7.66. 2,835,779 shares of the stock were exchanged, compared to its average volume of 1,406,079. Amneal Pharmaceuticals, Inc. has a 1-year low of $5.81 and a 1-year high of $9.48. The stock has a fifty day moving average of $8.05 and a two-hundred day moving average of $8.18. The firm has a market cap of $2.37 billion, a price-to-earnings ratio of -11.26 and a beta of 1.06.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last issued its earnings results on Friday, February 28th. The company reported $0.12 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.03). Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. The firm had revenue of $730.52 million for the quarter, compared to analyst estimates of $708.21 million. During the same period in the previous year, the company earned $0.14 earnings per share. Sell-side analysts forecast that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.